Payment overview · 2025
General Payments
$79.05
4 reported records · 3 companies
Healthcare provider profile · identity verified
Dean Meisel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WILMINGTON, NC · NPI 1982716502
Verified facts
What the public records show
CMS Open Payments records show Dean Meisel, MD received $79.05 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 55.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.51 | 55.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.53 | 24.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.01 | 20.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.05 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.51 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 567 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 337 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 108 |
| Omeprazole | Omeprazole | 272 | 85 |
| Lisinopril | Lisinopril | 214 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 69 |
| Valsartan | Valsartan | 201 | 53 |
| Losartan Potassium | Losartan Potassium | 173 | 56 |
| Gabapentin | Gabapentin | 162 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 51 |
| Potassium Chloride | Potassium Chloride | 148 | 44 |
| Sertraline Hcl | Sertraline Hcl | 145 | 44 |
| Furosemide | Furosemide | 138 | 49 |
| Metformin Hcl Er | Metformin Hcl | 138 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 35 |
| Ozempic | Semaglutide | 126 | 18 |
| Glimepiride | Glimepiride | 124 | 36 |
| Alprazolam | Alprazolam | 117 | 28 |
| Montelukast Sodium | Montelukast Sodium | 115 | 34 |
| Famotidine | Famotidine | 106 | 30 |
| Atenolol | Atenolol | 105 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 30 |
| Bupropion Xl | Bupropion Hcl | 96 | 26 |
| Eliquis | Apixaban | 93 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 38 |
| Allopurinol | Allopurinol | 84 | 26 |
| Meloxicam | Meloxicam | 81 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 24 |
| Trazodone Hcl | Trazodone Hcl | 79 | 24 |
| Farxiga | Dapagliflozin Propanediol | 77 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 23 |
| Lorazepam | Lorazepam | 71 | 27 |
| Simvastatin | Simvastatin | 71 | 21 |
| Spironolactone | Spironolactone | 69 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 25 |
| Clonazepam | Clonazepam | 64 | suppressed |
| Irbesartan | Irbesartan | 64 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 18 |
| Metformin Hcl | Metformin Hcl | 59 | 15 |
| Pregabalin | Pregabalin | 58 | 23 |
| Carvedilol | Carvedilol | 55 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 18 |
| Tramadol Hcl | Tramadol Hcl | 54 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 16 |
| Ezetimibe | Ezetimibe | 52 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | 15 |
| Prednisone | Prednisone | 49 | 36 |
| Alendronate Sodium | Alendronate Sodium | 48 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 12 |
| Cefdinir | Cefdinir | 45 | 42 |
| Mirtazapine | Mirtazapine | 45 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 44 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 14 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 12 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Jardiance | Empagliflozin | 39 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 28 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 14 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 24 |
| Finasteride | Finasteride | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | 17 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Azithromycin | Azithromycin | 16 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.05 · 4 records | AstraZeneca Pharmaceuticals LP | CAPVAXIVE, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, VAXELIS, VAXNEUVANCE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error